[Form 4] Beam Therapeutics Inc. Insider Trading Activity
Beam Therapeutics insider Bethany J. Cavanagh, who serves as SVP, Finance and Treasurer, reported a non‑discretionary sale of 467 shares of common stock on 10/01/2025 at a price of $24.53 per share. The filing shows 44,045 shares remained beneficially owned by the reporting person after the transaction. The form states the shares were sold automatically to cover tax withholding obligations arising from the vesting of restricted stock units granted on 9/30/2021 and 9/30/2024, and the sales were effected under a Rule 10b5‑1 trading plan adopted on 8/9/2024. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025.
Un dirigente interno di Beam Therapeutics, Bethany J. Cavanagh, che ricopre il ruolo di SVP, Finanza e Tesoriere, ha riportato una vendita non discrezionale di 467 azioni ordinarie in data 10/01/2025 al prezzo di $24.53 per azione. La comunicazione mostra che 44,045 azioni rimanevano beneficiariamente detenute dal soggetto segnalante dopo la transazione. Il modulo indica che le azioni sono state vendute automaticamente per coprire gli obblighi di withholding fiscale derivanti dall vesting delle unità azioni vincolate concesse il 9/30/2021 e il 9/30/2024, e che le vendite sono state effettuate nell'ambito di un piano di trading Rule 10b5‑1 adottato il 8/9/2024. Il Form 4 è stato firmato da un attorney‑in‑fact in data 10/03/2025.
Un directivo de Beam Therapeutics, Bethany J. Cavanagh, que se desempeña como SVP, Finanzas y Tesorera, reportó una venta no discrecional de 467 acciones ordinarias el 01/10/2025 a un precio de $24.53 por acción. El expediente muestra que 44,045 acciones permanecían poseídas de forma beneficiosa por la persona reportante después de la transacción. El formulario indica que las acciones se vendieron automáticamente para cubrir obligaciones de retención de impuestos derivadas del vesting de las unidades de acciones restringidas otorgadas el 30/09/2021 y el 30/09/2024, y las ventas se efectuaron bajo un plan de trading Rule 10b5‑1 adoptado el 09/08/2024. El Formulario 4 fue firmado por un apoderado el 03/10/2025.
Beam Therapeutics의 내부자 Bethany J. Cavanagh은 SVP, Finance and Treasurer를 맡고 있으며, 2025년 10월 1일 467주를 비재량적으로 매도했고 주당 가격은 $24.53였습니다. 제출서는 거래 후 보고자가 44,045주를 혜택적으로 보유하고 있음을 보여줍니다. 양식에 따르면 이 주식은 2021년 9월 30일 및 2024년 9월 30일에 부여된 제한 주식 단위(RSU)의 vesting으로 인한 세금 예치 의무를 충당하기 위해 자동으로 매도되었으며, 매도는 2024년 8월 9일에 채택된 Rule 10b5‑1 거래 계획에 따라 이루어졌습니다. 4 Form은 2025년 10월 3일에 대리인(attorney‑in‑fact)이 서명했습니다.
Une initiée de Beam Therapeutics, Bethany J. Cavanagh, qui occupe le poste de SVP, Finances et Trésorière, a signalé une vente non discrétionnaire de 467 actions ordinaires le 01/10/2025 à un prix de $24,53 par action. Le dossier indique que 44 045 actions restaient détenues bénéficiairement par la personne déclarante après la transaction. Le formulaire précise que les actions ont été vendues automatiquement pour couvrir les obligations de retenue fiscale liées à l’acquisition (vesting) des unités d’actions restreintes accordées le 30/09/2021 et le 30/09/2024, et que les ventes ont été effectuées dans le cadre d’un plan de négociation Rule 10b5‑1 adopté le 09/08/2024. Le Formulaire 4 a été signé par un mandataire le 03/10/2025.
Beam Therapeutics Insider Bethany J. Cavanagh, der als SVP, Finanzen und Schatzmeisterin tätig ist, meldete einen nicht-ermessenen Verkauf von 467 Stammaktien am 01.10.2025 zum Kurs von US$ 24,53 pro Aktie. Die Einreichung zeigt, dass nach der Transaktion 44.045 Aktien im wirtschaftlichen Eigentum der meldernden Person verbleiben. Das Formular besagt, dass die Aktien automatisch verkauft wurden, um Steuerabzugsverpflichtungen aus dem Vesting von Restricted Stock Units, die am 30.09.2021 und am 30.09.2024 gewährt wurden, zu decken, und die Verkäufe erfolgten unter einem am 09.08.2024 angenommenen Handelsplan gemäß Rule 10b5‑1. Das Formular 4 wurde am 03.10.2025 von einem Bevollmächtigten unterzeichnet.
أفاد المطلع من Beam Therapeutics، Bethany J. Cavanagh، التي تشغل منصب نائب الرئيس الأول للمالية والأمين، ببيع غير تقديري لــ467 سهماً من الأسهم العادية في 01/10/2025 بسعر قدره $24.53 للسهم الواحد. يُظهر الملف أن 44,045 سهماً بقيت مملوكهً لصاحب البلاغ بشكل مستفيد بعد الصفقة. يذكر النموذج أن الأسهم كانت مباعة تلقائياً لتغطية التزامات حجز الضرائب الناشئة عن vesting وحدات الأسهم المقيدة الممنوحة في 30/09/2021 و30/09/2024، وأن المبيعات تمت وفقاً لخطة تداول من نوع Rule 10b5‑1 المعتمدة في 08/09/2024. كما وقع النموذج 4 من قبل وكيل قانوني في 03/10/2025.
Beam Therapeutics 的内部人士 Bethany J. Cavanagh，担任 SVP，财务与总务，报告在 2025/10/01 以每股 $24.53 的价格非自由裁量地出售了 467 股普通股。申报显示交易后仍然持有受益所有权的股票为 44,045 股。表格指出这些股票是自动出售，以覆盖因授予于 2021/9/30 和 2024/9/30 的限制性股票单位（RSU）归属而产生的税款预扣义务，且此次出售遵循于 2024/8/9 通过的 Rule 10b5‑1 交易计划。Form 4 由代理人于 2025/10/03 签署。
- Sale was automatic under a Rule 10b5‑1 plan dated 8/9/2024, indicating planned, non‑discretionary trading
- Transaction explicitly covered tax withholding for RSU vesting on 9/30/2021 and 9/30/2024, clarifying the purpose of the sale
- Filing reports remaining beneficial ownership of 44,045 shares, providing transparency on insider holdings
- Disposition of 467 shares reduced the insider's stake, as reported
- Sale price of $24.53 realized on 10/01/2025, a concrete monetization event by an officer
Insights
TL;DR: Routine tax‑cover sale under a 10b5‑1 plan; no new grants or discretionary selling disclosed.
The report documents an automatic sale of 467 shares at $24.53 to satisfy tax withholding following RSU vesting on 9/30/2021 and 9/30/2024. The filing explicitly attributes the transaction to a pre‑existing Rule 10b5‑1 plan adopted on 8/9/2024, which indicates the sale was planned rather than discretionary.
This is a standard compliance disclosure under Section 16; the filing also records remaining beneficial ownership of 44,045 shares. No other derivative transactions, new grants, or departures are disclosed in this Form 4.
Un dirigente interno di Beam Therapeutics, Bethany J. Cavanagh, che ricopre il ruolo di SVP, Finanza e Tesoriere, ha riportato una vendita non discrezionale di 467 azioni ordinarie in data 10/01/2025 al prezzo di $24.53 per azione. La comunicazione mostra che 44,045 azioni rimanevano beneficiariamente detenute dal soggetto segnalante dopo la transazione. Il modulo indica che le azioni sono state vendute automaticamente per coprire gli obblighi di withholding fiscale derivanti dall vesting delle unità azioni vincolate concesse il 9/30/2021 e il 9/30/2024, e che le vendite sono state effettuate nell'ambito di un piano di trading Rule 10b5‑1 adottato il 8/9/2024. Il Form 4 è stato firmato da un attorney‑in‑fact in data 10/03/2025.
Un directivo de Beam Therapeutics, Bethany J. Cavanagh, que se desempeña como SVP, Finanzas y Tesorera, reportó una venta no discrecional de 467 acciones ordinarias el 01/10/2025 a un precio de $24.53 por acción. El expediente muestra que 44,045 acciones permanecían poseídas de forma beneficiosa por la persona reportante después de la transacción. El formulario indica que las acciones se vendieron automáticamente para cubrir obligaciones de retención de impuestos derivadas del vesting de las unidades de acciones restringidas otorgadas el 30/09/2021 y el 30/09/2024, y las ventas se efectuaron bajo un plan de trading Rule 10b5‑1 adoptado el 09/08/2024. El Formulario 4 fue firmado por un apoderado el 03/10/2025.
Beam Therapeutics의 내부자 Bethany J. Cavanagh은 SVP, Finance and Treasurer를 맡고 있으며, 2025년 10월 1일 467주를 비재량적으로 매도했고 주당 가격은 $24.53였습니다. 제출서는 거래 후 보고자가 44,045주를 혜택적으로 보유하고 있음을 보여줍니다. 양식에 따르면 이 주식은 2021년 9월 30일 및 2024년 9월 30일에 부여된 제한 주식 단위(RSU)의 vesting으로 인한 세금 예치 의무를 충당하기 위해 자동으로 매도되었으며, 매도는 2024년 8월 9일에 채택된 Rule 10b5‑1 거래 계획에 따라 이루어졌습니다. 4 Form은 2025년 10월 3일에 대리인(attorney‑in‑fact)이 서명했습니다.
Une initiée de Beam Therapeutics, Bethany J. Cavanagh, qui occupe le poste de SVP, Finances et Trésorière, a signalé une vente non discrétionnaire de 467 actions ordinaires le 01/10/2025 à un prix de $24,53 par action. Le dossier indique que 44 045 actions restaient détenues bénéficiairement par la personne déclarante après la transaction. Le formulaire précise que les actions ont été vendues automatiquement pour couvrir les obligations de retenue fiscale liées à l’acquisition (vesting) des unités d’actions restreintes accordées le 30/09/2021 et le 30/09/2024, et que les ventes ont été effectuées dans le cadre d’un plan de négociation Rule 10b5‑1 adopté le 09/08/2024. Le Formulaire 4 a été signé par un mandataire le 03/10/2025.
Beam Therapeutics Insider Bethany J. Cavanagh, der als SVP, Finanzen und Schatzmeisterin tätig ist, meldete einen nicht-ermessenen Verkauf von 467 Stammaktien am 01.10.2025 zum Kurs von US$ 24,53 pro Aktie. Die Einreichung zeigt, dass nach der Transaktion 44.045 Aktien im wirtschaftlichen Eigentum der meldernden Person verbleiben. Das Formular besagt, dass die Aktien automatisch verkauft wurden, um Steuerabzugsverpflichtungen aus dem Vesting von Restricted Stock Units, die am 30.09.2021 und am 30.09.2024 gewährt wurden, zu decken, und die Verkäufe erfolgten unter einem am 09.08.2024 angenommenen Handelsplan gemäß Rule 10b5‑1. Das Formular 4 wurde am 03.10.2025 von einem Bevollmächtigten unterzeichnet.
FAQ
What did Beam Therapeutics insider Bethany Cavanagh report on Form 4 (BEAM)?
Why were the shares sold according to the Form 4 for BEAM?
Was the sale by the BEAM reporting person discretionary?
How many shares did the reporting person own after the transaction?
Who signed the Form 4 for the filing?
